These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 24627057)

  • 1. [Treatment of rheumatoid arthritis in the Brazilian Unified National Health System: expenditures on infliximab compared to synthetic disease-modifying anti-rheumatic drugs, 2003-2006].
    Costa Jde O; Almeida AM; Guerra AA; Cherchiglia ML; Andrade EI; Acurcio Fde A
    Cad Saude Publica; 2014 Feb; 30(2):283-95. PubMed ID: 24627057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice.
    Virkki LM; Konttinen YT; Peltomaa R; Suontama K; Saario R; Immonen K; Jäntti J; Tuomiranta T; Nykänen P; Hämeenkorpi R; Heikkilä S; Isomäki P; Nordström D
    Clin Exp Rheumatol; 2008; 26(6):1059-66. PubMed ID: 19210870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of users of anticytokines offered by the health care system in the state of Paraná for the treatment of rheumatoid arthritis.
    Wiens A; Grochocki MC; Pontarolli DR; Venson R; Correr CJ; Pontarolo R
    Rev Bras Reumatol; 2012; 52(2):208-13. PubMed ID: 22460410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
    Mora C; González A; Díaz J; Quintana G
    Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment.
    Laas K; Peltomaa R; Kautiainen H; Puolakka K; Leirisalo-Repo M
    Ann Rheum Dis; 2006 Jul; 65(7):924-8. PubMed ID: 16339293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Peterson AN; Doyle J; Huse DM
    Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.
    Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M
    Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system.
    Mega TP; Silva RMD
    Rev Saude Publica; 2023; 57():41. PubMed ID: 37556663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Profile of spending on the treatment of rheumatoid arthritis for patients of the Unified Health System in the state of Minas Gerais - 2008-2013].
    Silva GDD; Andrade EIG; Cherchiglia ML; Almeida AM; Guerra Júnior AA; Acurcio FA
    Cien Saude Colet; 2018 Apr; 23(4):1241-1253. PubMed ID: 29694580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expenses of the Brazilian Ministry of Health for high-cost drugs: a demographic and clinical analysis].
    Brandão CM; Guerra AA; Cherchiglia ML; Andrade EI; Almeida AM; da Silva GD; de Queiroz OV; Faleiros DR; Acurcio Fde A
    Value Health; 2011; 14(5 Suppl 1):S71-7. PubMed ID: 21839903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapeutic profile of users and expenditure on high-cost drugs in São Leopoldo, Rio Grande do Sul State, Brazil, 2014.
    Sopelsa M; Motter FR; Barcellos NT; Leite HM; Paniz VMV
    Epidemiol Serv Saude; 2017; 26(4):759-770. PubMed ID: 29211140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
    Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
    Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis.
    Walsh CA; Minnock P; Slattery C; Kennedy N; Pang F; Veale DJ; Bresnihan B; FitzGerald O
    Rheumatology (Oxford); 2007 Jul; 46(7):1148-52. PubMed ID: 17478471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of anti-tumor necrosis factor agents.
    Wong JB
    Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S65-70. PubMed ID: 15552517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.